Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ganetespib
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-12 of 12 for your search:
Start Over
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-14, NCT01798485
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Approved-not yet active
Age: 60 and over
Sponsor: Other
Protocol IDs: AML18, NCT02272478
Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL/12/0158, CMS # 1995, A15183, 2012-001598-10, TBC, NCT01590160
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: GYN-064, NCI-2013-01416, IRB#13-028/ERP-GYN-064, P30CA006927, NCT01962948
A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SARC023, NCT02008877
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GANNET53, 2013-003868-31, NCT02012192
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-1195, NCT02261805
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-477, NCT01560416
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NYU S12-03732, NCI-2014-00177, P30CA016087, NCT02060253
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140150, 14-C-0150, NCT02192541
A Study of Ganetespib in Combination With Chemoradiation
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0815, NCI-2015-00492, NCT02389751
Ganetespib Window of Opportunity Study in Head and Neck Cancers
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 to 79
Sponsor: Other
Protocol IDs: IRB00070264, WINSHIP2572-13, NCI-2014-02605, NCT02334319
Start Over